Endocarditis: Difference between revisions
No edit summary |
|||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 11: | Line 11: | ||
}} | }} | ||
{{endocarditis}} | {{endocarditis}} | ||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' {{Maliha}}, {{CZ}}; [[Michael W. Tempelhof]] M.D., {{DN}} | {{CMG}}; '''Associate Editor(s)-In-Chief:''' {{Fs}}, {{Maliha}}, {{CZ}}; [[Michael W. Tempelhof]] M.D., {{DN}} | ||
{{SK}} Infective Endocarditis (IE); Subacute bacterial endocarditis (SBE); Acute bacterial endocarditis; Fungal endocarditis; Nosocomial infective endocarditis; Intravenous drug abuse endocarditis; Intravenous drug abuse infective endocarditis; Prosthetic valve endocarditis; Endocardial infection; Native valve endocarditis; HACEK endocarditis; Bloodstream infection | {{SK}} Infective Endocarditis (IE); Subacute bacterial endocarditis (SBE); Acute bacterial endocarditis; Fungal endocarditis; Nosocomial infective endocarditis; Intravenous drug abuse endocarditis; Intravenous drug abuse infective endocarditis; Prosthetic valve endocarditis; Endocardial infection; Native valve endocarditis; HACEK endocarditis; Bloodstream infection | ||
| Line 37: | Line 37: | ||
==Treatment== | ==Treatment== | ||
[[Endocarditis medical therapy|Medical Therapy]] | [[Endocarditis antithrombotic therapy|Antithrombotic Therapy]] | | [[Endocarditis medical therapy|Medical Therapy]] | | [[Endocarditis surgery|Surgery]] | [[Endocarditis antithrombotic therapy|Antithrombotic Therapy]] | [[Endocarditis primary prevention|Primary Prevention]] | [[Endocarditis secondary prevention|Secondary Prevention]] | ||
[[Endocarditis | |||
==2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease== | ==2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease== | ||
Latest revision as of 23:36, 12 December 2020
 |
Resident Survival Guide |
| Endocarditis | |
 | |
|---|---|
| Mitral valve vegetations in a patient with bacterial endocarditis. |
|
Endocarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
|
Case Studies |
|
Endocarditis On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Fahimeh Shojaei, M.D., Maliha Shakil, M.D. [2], Cafer Zorkun, M.D., Ph.D. [3]; Michael W. Tempelhof M.D., Dima Nimri, M.D. [4]
Synonyms and keywords: Infective Endocarditis (IE); Subacute bacterial endocarditis (SBE); Acute bacterial endocarditis; Fungal endocarditis; Nosocomial infective endocarditis; Intravenous drug abuse endocarditis; Intravenous drug abuse infective endocarditis; Prosthetic valve endocarditis; Endocardial infection; Native valve endocarditis; HACEK endocarditis; Bloodstream infection
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Endocarditis for other Disorders
Risk Factors
Epidemiology and Demographics
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination and Signs | Laboratory Findings | Chest X Ray | Electrocardiogram | Cardiac MRI | CT | Echocardiography
Treatment
Medical Therapy | | Surgery | Antithrombotic Therapy | Primary Prevention | Secondary Prevention
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Diagnosis and Follow-up | Endocarditis Medical Therapy Guidelines | Endocarditis Intervention Guidelines